{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:09:46Z","timestamp":1793261386463,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Roche Laboratories Inc"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1053\/j.ajkd.2015.06.013","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T21:56:15Z","timestamp":1437515775000},"page":"783-791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["Randomized Controlled Trial of Mycophenolate Mofetil in Children, Adolescents, and Adults With IgA Nephropathy"],"prefix":"10.1053","volume":"66","clinical-trial-number":[{"clinical-trial-number":"isrctn62574616","registry":"10.18810\/isrctn"},{"clinical-trial-number":"nct00318474","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ronald J.","family":"Hogg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Curtis","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Charles","family":"Jennette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sibley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Appel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cattran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Morrison","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Gipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"245","key":"10.1053\/j.ajkd.2015.06.013_bib1","first-page":"709","article-title":"The commonest glomerulonephritis in the world: IgA nephropathy","volume":"64","author":"D\u2019Amico","year":"1987","journal-title":"Q\u00a0J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2015.06.013_bib2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s004670000517","article-title":"Evidence-based assessment of treatment options for children with IgA nephropathies","volume":"16","author":"Wyatt","year":"2001","journal-title":"Pediatr Nephrol"},{"issue":"25","key":"10.1053\/j.ajkd.2015.06.013_bib3","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2015.06.013_bib4","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1681\/ASN.2011030221","article-title":"Current therapy for IgA nephropathy","volume":"22","author":"Floege","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2015.06.013_bib5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0272-6386(12)80980-2","article-title":"Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other anti-hypertensive agents and to patients receiving no therapy","volume":"23","author":"Cattran","year":"1994","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2015.06.013_bib6","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","article-title":"Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial","volume":"14","author":"Praga","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2015.06.013_bib7","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1681\/ASN.2006040347","article-title":"IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria","volume":"18","author":"Coppo","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2015.06.013_bib8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/ndt\/gfg090","article-title":"Effect of losartan and amlodipine on proteinuria and transforming growth factor-\u03b21 in patients with IgA nephropathy","volume":"18","author":"Park","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"18","key":"10.1053\/j.ajkd.2015.06.013_bib9","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1056\/NEJM199411033311804","article-title":"A\u00a0controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group","volume":"331","author":"Donadio","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2015.06.013_bib10","first-page":"796","article-title":"A\u00a0randomized control trial of mycophenolate mofetil treatment in severe IgA nephropathy","volume":"82","author":"Chen","year":"2002","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"2","key":"10.1053\/j.ajkd.2015.06.013_bib11","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","article-title":"Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2015.06.013_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ki.2009.499","article-title":"Long-term study of mycophenolate mofetil treatment in IgA nephropathy","volume":"77","author":"Tang","year":"2010","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2015.06.013_bib13","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2015.06.013_bib14","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial","volume":"20","author":"Frisch","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"2 suppl 2","key":"10.1053\/j.ajkd.2015.06.013_bib15","first-page":"10","article-title":"In\u00a0vitro immunosuppressive effects of mycophenolic acid and an ester pro drug, RS-61443","volume":"23","author":"Allison","year":"1991","journal-title":"Transplant Proc"},{"issue":"11","key":"10.1053\/j.ajkd.2015.06.013_bib16","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.V9112055","article-title":"Mycophenolic acid: a novel approach to therapy of experimental mesangial proliferative glomerulonephritis","volume":"9","author":"Ziswiler","year":"1998","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2015.06.013_bib17","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Toronto Glomerulonephritis Registry: remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2015.06.013_bib18","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlation, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2015.06.013_bib19","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/ki.2010.43","article-title":"The Oxford IgA nephropathy clinicopathological classifications: as valid for children as for adults:","volume":"77","author":"Coppo","year":"2010","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2015.06.013_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2369-5-3","article-title":"A\u00a0randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616]","volume":"5","author":"Hogg","year":"2004","journal-title":"BMC Nephrol"},{"key":"10.1053\/j.ajkd.2015.06.013_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A\u00a0coefficient of agreement for nominal scale","volume":"20","author":"Cohen","year":"1960","journal-title":"Educat Psychol Measure"},{"issue":"2","key":"10.1053\/j.ajkd.2015.06.013_bib22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1542\/peds.58.2.259","article-title":"A\u00a0simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine","volume":"58","author":"Schwartz","year":"1976","journal-title":"Pediatrics"},{"issue":"1","key":"10.1053\/j.ajkd.2015.06.013_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"5","key":"10.1053\/j.ajkd.2015.06.013_bib24","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000168483","article-title":"Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis","volume":"29","author":"Xu","year":"2009","journal-title":"Am J Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2015.06.013_bib25","first-page":"780","article-title":"Mycophenolate mofetil in the treatment of IgA nephropathy: a systematic review","volume":"49","author":"Tan","year":"2008","journal-title":"Singapore Med J"},{"issue":"2","key":"10.1053\/j.ajkd.2015.06.013_bib26","first-page":"198","article-title":"Long-term effects of methylprednisolone pulses and mycophenolate mofetil in IgA nephropathy patients at risk of progression","volume":"25","author":"Roccatello","year":"2012","journal-title":"J\u00a0Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2015.06.013_bib27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/ki.2011.126","article-title":"Validation of the Oxford classification of IgA nephropathy","volume":"80","author":"Herzenberg","year":"2011","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2015.06.013_bib28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00467-011-2057-9","article-title":"Treatment of children with Henoch-Sch\u00f6nlein purpura nephritis with mycophenolate mofetil","volume":"27","author":"Du","year":"2012","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2015.06.013_bib29","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/ndt\/gfr339","article-title":"Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification)","volume":"27","author":"Edst\u00f6m Halling","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2015.06.013_bib30","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/ndt\/gfr295","article-title":"The Oxford classification as a predictor of prognosis in patients with IgA nephropathy","volume":"27","author":"Kang","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1053\/j.ajkd.2015.06.013_bib31","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2215\/CJN.08440811","article-title":"Validating the Oxford classification of IgA nephropathy","volume":"6","author":"Troyanov","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2015.06.013_bib32","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2015.06.013_bib33","doi-asserted-by":"crossref","first-page":"e71545","DOI":"10.1371\/journal.pone.0071545","article-title":"Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638615008677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638615008677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:43:27Z","timestamp":1759459407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638615008677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0272638615008677"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.06.013","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725671067.793513962","asserted-by":"object"}]},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Controlled Trial of Mycophenolate Mofetil in Children, Adolescents, and Adults With IgA Nephropathy","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}